Avicanna Inc. (AVCNF)
| Previous close | 0.2295 |
| Open | 0.2900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.2900 - 0.2900 |
| 52-week range | 0.1780 - 0.5320 |
| Volume | |
| Avg. volume | 6,487 |
| Market cap | 35.44M |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAvicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammationTORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence (“RWE”) study using RHO Phyto br
Simply Wall St.Avicanna Full Year 2023 Earnings: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)
Avicanna ( TSE:AVCN ) Full Year 2023 Results Key Financial Results Revenue: CA$16.8m (up 315% from FY 2022). Net loss...
GlobeNewswireAvicanna Reports Full Year 2023 Audited Financial Results
$16.8M in Revenue, representing an increase of 314% from 2022$6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements. 2023 FINANCIAL HIGHLIG
